Diasorin said it will invest about €10 million to commercialize its Liaison Nes point‑of‑care PCR platform in the U.S., building a 30‑person sales force and partnering with Thermo Fisher and McKesson for distribution. The Liaison Nes already holds FDA 510(k) clearance and a CLIA waiver for a four‑target respiratory panel and Diasorin expects U.S. revenue contribution by Q3. The company also disclosed consolidation of manufacturing—closing a Germany plant and shifting production to Italy—and a strategic pivot in China toward specialty testing amid a changing procurement environment. Diasorin has submitted a gastrointestinal panel for Nes to the FDA and anticipates clearance in H1.